-
1 Comment
Shinhung Co., Ltd is currently in a long term uptrend where the price is trading 23.4% above its 200 day moving average.
From a valuation standpoint, the stock is 88.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.0.
Shinhung Co., Ltd's total revenue sank by 7.7% to $30B since the same quarter in the previous year.
Its net income has increased by 367.1% to $5B since the same quarter in the previous year.
Finally, its free cash flow fell by 137.3% to $-11B since the same quarter in the previous year.
Based on the above factors, Shinhung Co., Ltd gets an overall score of 3/5.
| Sector | Healthcare |
|---|---|
| Industry | Medical Devices |
| Exchange | KO |
| CurrencyCode | KRW |
| ISIN | KR7004080008 |
| Dividend Yield | 1.0% |
|---|---|
| Market Cap | 137B |
| Target Price | None |
| Beta | 0.04 |
| PE Ratio | None |
Shinhung Co., Ltd. manufactures, imports, and sells dental products and supplies in South Korea. Its products include implant systems; dental units and chairs; dental alloys, such as composition tables, crowns, and porcelain under the Goldenian brand name; prefabricates SS crowns; taurus, insert, and mobile cabinets; compressors and mixers; dental needles; dental porcelain powder and laboratory products; and disposable needles, dental operatories, and autoclaves and X-ray equipment. The company also offers loan services for dentists. Shinhung Co., Ltd. was founded in 1955 and is headquartered in Seoul, South Korea.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 004080.KO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
